Colitis

Summary

Colitis (MONDO:0005292) is a disease (an umbrella term covering 9 Mondo subtypes) with 2 cohort genes (1 GWAS associations across 13 studies) and 46 clinical trials. Top therapeutic interventions include infliximab, loperamide, and ganciclovir.

At a glance

• Umbrella term: 9 Mondo subtypes
• Cohort genes: 2
• GWAS associations: 1
• ClinVar variants: 6
• Clinical trials: 46

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	colitis
Mondo ID	MONDO:0005292
EFO	EFO:0003872
MeSH	D003092
DOID	DOID:0060180
ICD-11	1870792958
NCIT	C26723
SNOMED CT	64226004
UMLS	C0009319
MedGen	40385
Is cancer (heuristic)	no

Also known as: colitis · colitis (disease) · colon inflammation · inflammation of colon

Data availability: 6 ClinVar variants · 1 GWAS association (13 studies) · 1 HPO phenotype.

Disease family

An umbrella term covering 9 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › gastroenteritis › colitis

Related subtypes (8): inflammatory diarrhea, intestinal infectious disease, intestinal tuberculosis, appendicitis, campylobacteriosis, Salmonella gastroenteritis, eosinophilic gastroenteritis, enteritis

Subtypes (9): ischemic colitis, microscopic colitis, chemical colitis, diversion colitis, ulcerative colitis, ileocolitis, indeterminate colitis, infectious colitis, proctocolitis

Genetics & variants

GWAS landscape

1 GWAS associations across 13 studies. Top hits map to 2 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs115378818	6e-15	TSBP1, TSBP1-AS1	?	2.43

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90080237	Backman JD	2021	19,104	362,399	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084223	Backman JD	2021	19,104	362,399	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90080236	Backman JD	2021	17,883	365,747	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084222	Backman JD	2021	17,883	365,747	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90726997	Kim HI	2026	2,033	41,993	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90077865	Backman JD	2021	1,203	330,551	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90081851	Backman JD	2021	1,203	330,551	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90077866	Backman JD	2021	1,104	327,948	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90081852	Backman JD	2021	1,104	327,948	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90080235	Backman JD	2021	650	387,279	Exome sequencing and analysis of 454,787 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intron_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs115378818	6	32333650	C>T		intron_variant	TSBP1, TSBP1-AS1	6e-15	Tier 4: intronic/intergenic

ClinVar germline variants

6 retrieved; paginated sample, class counts are floors:

2 uncertain significance, 2 likely pathogenic, 1 conflicting classifications of pathogenicity, 1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
989389	NM_003177.7(SYK):c.1649C>A (p.Ser550Tyr)	SYK	Pathogenic	criteria provided, single submitter
989237	NM_003177.7(SYK):c.1350G>A (p.Met450Ile)	SYK	Likely pathogenic	criteria provided, single submitter
989387	NM_003177.7(SYK):c.1024C>A (p.Pro342Thr)	SYK	Likely pathogenic	criteria provided, single submitter
989386	NM_003177.7(SYK):c.1649C>T (p.Ser550Phe)	SYK	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2571633	NM_015695.3(BRPF3):c.1978C>T (p.Leu660Phe)	BRPF3	Uncertain significance	criteria provided, single submitter
989236	NM_003177.7(SYK):c.1057G>A (p.Ala353Thr)	SYK	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SYK	Orphanet:695807	Immunodeficiency-systemic inflammation-lymphoma predisposition syndrome

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SYK	HGNC:11491	ENSG00000165025	P43405	Tyrosine-protein kinase SYK	clinvar
BRPF3	HGNC:14256	ENSG00000096070	Q9ULD4	Bromodomain and PHD finger-containing protein 3	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SYK	Tyrosine-protein kinase SYK	Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR).
BRPF3	Bromodomain and PHD finger-containing protein 3	Scaffold subunit of various histone acetyltransferase (HAT) complexes, such as the MOZ/MORF and HBO1 complexes, which have a histone H3 acetyltransferase activity.

Protein-family classification

Druggable: 1 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	13.9×	0.142
Transcription factor	1	4.1×	0.228

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SYK	Kinase	yes	2.7.10.2	Prot_kinase_dom, SH2, Ser-Thr/Tyr_kinase_cat_dom
BRPF3	Transcription factor	no		PWWP_dom, Bromodomain, Znf_PHD

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
leukocyte	1
monocyte	1
mononuclear cell	1
ganglionic eminence	1
sural nerve	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SYK	239	broad	marker	monocyte, mononuclear cell, leukocyte
BRPF3	209	ubiquitous	marker	ganglionic eminence, ventricular zone, sural nerve

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
SYK	5,172
BRPF3	1,462

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
SYK	P43405	93
BRPF3	Q9ULD4	1

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 58. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Platelet activation, signaling and aggregation	2	105.7×	0.005	SYK, BRPF3
FLT3 signaling through SRC family kinases	1	815.7×	0.013	SYK
Interleukin-2 signaling	1	475.8×	0.013	SYK
FCGR activation	1	439.2×	0.013	SYK
Interleukin-2 family signaling	1	317.2×	0.013	SYK
Role of LAT2/NTAL/LAB on calcium mobilization	1	300.5×	0.013	SYK
Signaling by CSF3 (G-CSF)	1	285.5×	0.013	SYK
Regulation of signaling by CBL	1	248.3×	0.013	SYK
DAP12 interactions	1	237.9×	0.013	SYK
Role of phospholipids in phagocytosis	1	228.4×	0.013	SYK
Regulation of TP53 Activity through Acetylation	1	228.4×	0.013	BRPF3
Platelet Aggregation (Plug Formation)	1	219.6×	0.013	SYK
Inactivation of CSF3 (G-CSF) signaling	1	219.6×	0.013	SYK
Integrin signaling	1	211.5×	0.013	SYK
Dectin-2 family	1	211.5×	0.013	SYK
Anti-inflammatory response favouring Leishmania parasite infection	1	196.9×	0.013	SYK
Leishmania parasite growth and survival	1	196.9×	0.013	SYK
DAP12 signaling	1	184.2×	0.013	SYK
FCERI mediated Ca+2 mobilization	1	178.4×	0.013	SYK
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	1	178.4×	0.013	SYK
FCERI mediated MAPK activation	1	173.0×	0.013	SYK
FLT3 Signaling	1	173.0×	0.013	SYK
Parasite infection	1	173.0×	0.013	SYK
Leishmania phagocytosis	1	173.0×	0.013	SYK
Signaling by the B Cell Receptor (BCR)	1	173.0×	0.013	SYK
Hemostasis	2	36.0×	0.013	SYK, BRPF3
Interleukin-3, Interleukin-5 and GM-CSF signaling	1	158.6×	0.013	SYK
GPVI-mediated activation cascade	1	154.3×	0.013	SYK
FCGR3A-mediated IL10 synthesis	1	146.4×	0.014	SYK
Fcgamma receptor (FCGR) dependent phagocytosis	1	139.3×	0.014	SYK

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of interleukin-3 production	1	8426.0×	0.003	SYK
regulation of superoxide anion generation	1	8426.0×	0.003	SYK
regulation of arachidonate secretion	1	8426.0×	0.003	SYK
regulation of neutrophil degranulation	1	4213.0×	0.004	SYK
cellular response to lectin	1	4213.0×	0.004	SYK
leukocyte activation involved in immune response	1	2808.7×	0.004	SYK
serotonin secretion by platelet	1	2808.7×	0.004	SYK
beta selection	1	2808.7×	0.004	SYK
cellular response to molecule of fungal origin	1	2106.5×	0.004	SYK
positive regulation of mast cell cytokine production	1	1685.2×	0.004	SYK
regulation of platelet activation	1	1404.3×	0.004	SYK
positive regulation of alpha-beta T cell proliferation	1	1404.3×	0.004	SYK
interleukin-3-mediated signaling pathway	1	1203.7×	0.004	SYK
regulation of developmental process	1	1203.7×	0.004	BRPF3
regulation of platelet aggregation	1	1203.7×	0.004	SYK
gamma-delta T cell differentiation	1	1053.2×	0.004	SYK
lymph vessel development	1	936.2×	0.004	SYK
neutrophil activation involved in immune response	1	936.2×	0.004	SYK
positive regulation of gamma-delta T cell differentiation	1	936.2×	0.004	SYK
cell activation	1	842.6×	0.004	SYK
positive regulation of alpha-beta T cell differentiation	1	842.6×	0.004	SYK
regulation of phagocytosis	1	842.6×	0.004	SYK
positive regulation of mast cell degranulation	1	766.0×	0.004	SYK
obsolete regulation of DNA-binding transcription factor activity	1	766.0×	0.004	SYK
regulation of hemopoiesis	1	766.0×	0.004	BRPF3
cell surface pattern recognition receptor signaling pathway	1	702.2×	0.004	SYK
leukotriene biosynthetic process	1	648.1×	0.005	SYK
collagen-activated tyrosine kinase receptor signaling pathway	1	648.1×	0.005	SYK
positive regulation of monocyte chemotactic protein-1 production	1	601.9×	0.005	SYK
macrophage activation involved in immune response	1	561.7×	0.005	SYK

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Infliximab	Phase 3 (in late-stage trials)
Methylprednisolone	Phase 3 (in late-stage trials)
Prednisolone	Phase 3 (in late-stage trials)
Ustekinumab	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Adalimumab, Mesalamine, Tacrolimus Anhydrous, Tofacitinib, Vedolizumab.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
SYK	FEDRATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SYK	54	4
BRPF3	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
FEDRATINIB	4	SYK
NERATINIB	4	SYK
INFIGRATINIB PHOSPHATE	4	SYK
INFIGRATINIB	4	SYK
ENTRECTINIB	4	SYK
FOSTAMATINIB	4	SYK
CERITINIB	4	SYK
BOSUTINIB	4	SYK
GILTERITINIB	4	SYK
FOSTAMATINIB DISODIUM	4	SYK
PAZOPANIB	4	SYK
DASATINIB	4	SYK
ERLOTINIB	4	SYK
CRIZOTINIB	4	SYK
MIDOSTAURIN	4	SYK
IMATINIB	4	SYK
ENTOSPLETINIB	3	SYK
CEDIRANIB	3	SYK
QUERCETIN	3	SYK
LESTAURTINIB	3	SYK
FORETINIB	2	SYK
LUTEOLIN	2	SYK
REBASTINIB	2	SYK
APITOLISIB	2	SYK
CENISERTIB	2	SYK
ADAVOSERTIB	2	SYK
ILORASERTIB	2	SYK
R-343	2	SYK
FISETIN	2	SYK
TOP-1288	2	SYK

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
SYK	873	Binding:863, Functional:10
BRPF3	89	Binding:88, Functional:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
SYK	2.7.10.2, 2.7.12.1	non-specific protein-tyrosine kinase, dual-specificity kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
SYK	873

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
FEDRATINIB	4	SYK
NERATINIB	4	SYK
INFIGRATINIB PHOSPHATE	4	SYK
INFIGRATINIB	4	SYK
ENTRECTINIB	4	SYK
FOSTAMATINIB	4	SYK
CERITINIB	4	SYK
BOSUTINIB	4	SYK
GILTERITINIB	4	SYK
FOSTAMATINIB DISODIUM	4	SYK
PAZOPANIB	4	SYK
DASATINIB	4	SYK
ERLOTINIB	4	SYK
CRIZOTINIB	4	SYK
MIDOSTAURIN	4	SYK
IMATINIB	4	SYK
ENTOSPLETINIB	3	SYK
CEDIRANIB	3	SYK
QUERCETIN	3	SYK
LESTAURTINIB	3	SYK
FORETINIB	2	SYK
LUTEOLIN	2	SYK
REBASTINIB	2	SYK
APITOLISIB	2	SYK
CENISERTIB	2	SYK
ADAVOSERTIB	2	SYK
ILORASERTIB	2	SYK
R-343	2	SYK
FISETIN	2	SYK
TOP-1288	2	SYK

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	SYK
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	BRPF3

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
BRPF3	89	—

Clinical trials & evidence

Clinical trials

Clinical trials: 46.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	27
PHASE2	6
PHASE1	6
PHASE3	4
PHASE4	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02687724	PHASE4	UNKNOWN	Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis
NCT05947669	PHASE3	RECRUITING	Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis
NCT07047339	PHASE2/PHASE3	RECRUITING	Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis
NCT01369329	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
NCT01369342	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease (UNITI-2)
NCT01369355	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease (IM-UNITI)
NCT04407247	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
NCT07012395	PHASE2	RECRUITING	A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT00072943	PHASE2	COMPLETED	A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn’s Disease
NCT00514982	PHASE2	WITHDRAWN	Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome
NCT00533078	PHASE2	COMPLETED	Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies
NCT02647866	PHASE2	COMPLETED	Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
NCT05726396	PHASE2	WITHDRAWN	A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis
NCT03819296	PHASE1	RECRUITING	Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
NCT04038619	PHASE1	RECRUITING	Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT07196410	PHASE1	RECRUITING	KAN-004 for Immune-Related Diarrhea or Colitis
NCT00000768	PHASE1	COMPLETED	A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients
NCT00325013	PHASE1	COMPLETED	Evaluation of DHA for the Treatment of PSC
NCT03378167	PHASE1	COMPLETED	PediCRaFT: Pediatric Crohn’s Disease Fecal Transplant Trial
NCT06206707	Not specified	RECRUITING	FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis
NCT06424769	Not specified	ENROLLING_BY_INVITATION	Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
NCT07541261	Not specified	NOT_YET_RECRUITING	A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn’s Disease in Saudi Arabia
NCT00002273	Not specified	COMPLETED	A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS
NCT00184171	Not specified	TERMINATED	Treatment of Microscopic Colitis
NCT00272818	Not specified	COMPLETED	Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
NCT00518349	Not specified	COMPLETED	Colonoscope Passive Bending Function
NCT00936585	Not specified	TERMINATED	NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn’s Disease
NCT01326013	Not specified	COMPLETED	A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel
NCT01346059	Not specified	TERMINATED	Intracolonic Vancomycin Therapy in Severe C. Diff Colitis
NCT02063282	Not specified	COMPLETED	The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers
NCT02333526	Not specified	UNKNOWN	Syndecan 1 as Biomarker for Inflammation
NCT02503514	Not specified	COMPLETED	Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort
NCT02569333	Not specified	COMPLETED	Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis
NCT02600143	Not specified	COMPLETED	Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.
NCT02709213	Not specified	COMPLETED	Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy
NCT02768038	Not specified	WITHDRAWN	Intestinal Microbiome and Chronic Inflammatory Bowel Disease
NCT03014284	Not specified	WITHDRAWN	Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis
NCT03548948	Not specified	COMPLETED	Obesity, Iron Regulation and Colorectal Cancer Risk
NCT03601611	Not specified	COMPLETED	Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms
NCT04272307	Not specified	UNKNOWN	MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
INFLIXIMAB	4	4
LOPERAMIDE	4	3
GANCICLOVIR	4	2
VEDOLIZUMAB	4	2
FISH OIL TRIGLYCERIDES	4	1
GOLIMUMAB	4	1
MESALAMINE	4	1
ROCATINLIMAB	3	1
GLUTAMIC ACID HYDROCHLORIDE	1	1
CHEMBL3920741	0	1
CHEMBL3137673	0	1